PBPK‐led assessment of antimalarial drugs as candidates for Covid‐19: Simulating concentrations at the site of action to inform repurposing strategies
Clinical and Translational Science · 2024
DOI: 10.1111/cts.13865 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Nada Abla und 5 weiteren Autor:innen. Beteiligte Einrichtung: MMV Medicines for Malaria Venture, Geneva, Switzerland. Hauptthemen laut MEDLINE: Antimalarials, Drug Repositioning, Amodiaquine, COVID-19 Drug Treatment. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The urgent need for safe, efficacious, and accessible drug treatments to treat coronavirus disease 2019 (COVID‐19) prompted a global effort to evaluate drug repurposing opportunities. Pyronaridine and amodiaquine are both components of approved antimalarials with in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). In vitro activity does not always translate to clinical efficacy across a therapeutic dose range. This study applied available, verified, physiologically based pharmacokinetic (PBPK) models for pyronaridine, amodiaquine, and its active metabolite N‐desethylamodiaquine (DEAQ) to predict drug concentrations in lung tissue relative to plasma or blood in the default healthy virtual population. Lung exposures were compared to published data across the reported range of in vitro EC 50 values against SARS‐CoV‐2. In the multicompartment permeability‐limited PBPK model, the predicted total C max in lung mass for pyronaridine was 34.2 μM on Day 3, 30.5‐fold greater than in blood (1.12 μM) and for amodiaquine was 0.530 μM, 8.83‐fold greater than in plasma (0.060 μM). In the perfusion‐limited PBPK model, the DEAQ predicted total C max on Day 3 in lung mass (30.2 μM) was 21.4‐fold greater than for plasma (1.41 μM). Based on the available in vitro data, predicted drug concentrations in lung tissue for pyronaridine and DEAQ, but not amodiaquine, appeared sufficient to inhibit SARS‐CoV‐2 replication. Simulations indicated standard dosing regimens of pyronaridine‐artesunate and artesunate‐amodiaquine have potential to treat COVID‐19. These findings informed repurposing strategies to select the most relevant compounds for clinical investigation in COVID‐19. Clinical data for model verification may become available from ongoing clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- MMV Medicines for Malaria Venture, Geneva, Switzerland.
- Certara UK Ltd, Sheffield, UK.
- Magenta Communications Ltd, Abingdon, UK.
ORCID-Profile: Nada Abla, Lisa M Almond, Jennifer J Bonner, Naomi Richardson, Timothy N C Wells, Jörg J Möhrle
Zitieren
APA
Abla, N., Almond, L. M., Bonner, J. J., Richardson, N., Wells, T. N. C., & Möhrle, J. J. (2024). PBPK‐led assessment of antimalarial drugs as candidates for Covid‐19: Simulating concentrations at the site of action to inform repurposing strategies. Clinical and Translational Science. https://doi.org/10.1111/cts.13865
Vancouver
Abla N, Almond LM, Bonner JJ, Richardson N, Wells TNC, Möhrle JJ. PBPK‐led assessment of antimalarial drugs as candidates for Covid‐19: Simulating concentrations at the site of action to inform repurposing strategies. Clinical and Translational Science. 2024. doi:10.1111/cts.13865
BibTeX
@article{Abla2024,
author = {Abla, Nada and Almond, Lisa M and Bonner, Jennifer J and Richardson, Naomi and Wells, Timothy N C and Möhrle, Jörg J},
title = {PBPK‐led assessment of antimalarial drugs as candidates for Covid‐19: Simulating concentrations at the site of action to inform repurposing strategies},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.13865}
}
EUVIMED